Feedback

Epigral Limited Announces Financial Results and Key Decisions from Board Meeting

Outcome of Board Meeting Held on 24th July 2024

Mumbai, India – Epigral Limited (formerly known as Meghmani Finechem Limited) has announced key outcomes from its Board Meeting held on 24th July 2024. The Board approved the un-audited financial results for the first quarter ended 30th June 2024.

Key Resolutions Approved

The Board of Directors approved the following resolutions:

H2: Un-Audited Financial Results

H3: Standalone Financial Results

Revenue and Income:

• Revenue from Operations: ₹651.20 crores
• Other Income: ₹2.40 crores
• Total Income: ₹653.60 crores

Expenses:

• Cost of Materials Consumed: ₹339.48 crores
• Changes in Inventories: ₹19.87 crores
• Employee Benefits: ₹27.40 crores
• Finance Costs: ₹14.25 crores
• Depreciation and Amortisation: ₹33.45 crores
• Power and Fuel: ₹30.31 crores
• Other Expenses: ₹57.74 crores
• Total Expenses: ₹522.50 crores

Profit Metrics:

• Profit Before Tax: ₹131.10 crores
• Net Profit: ₹86.01 crores
• Earnings Per Share (Basic and Diluted): ₹20.70

H3: Consolidated Financial Results

Revenue and Income:

• Revenue from Operations: ₹651.20 crores
• Other Income: ₹2.40 crores
• Total Income: ₹653.60 crores

Expenses:

• Cost of Materials Consumed: ₹339.48 crores
• Changes in Inventories: ₹19.87 crores
• Employee Benefits: ₹27.40 crores
• Finance Costs: ₹14.25 crores
• Depreciation and Amortisation: ₹33.45 crores
• Power and Fuel: ₹30.31 crores
• Other Expenses: ₹57.74 crores
• Total Expenses: ₹522.50 crores

Profit Metrics:

• Profit Before Tax: ₹130.96 crores
• Net Profit: ₹85.87 crores
• Earnings Per Share (Basic and Diluted): ₹20.67

Additional Highlights

• Limited Review Report: The Board took on record the 'Limited Review Report' issued by M/s. S R B C & CO LLP, Statutory Auditors of the Company.
• Meeting Details: The Board Meeting commenced at 11:00 a.m. and concluded at 01:00 p.m. at the registered office in Ahmedabad.

Annexure: Financial Details

Standalone Financial Results for Q1 FY2024-25

Particulars	June 30, 2024 (₹ Cr)	March 31, 2024 (₹ Cr)	June 30, 2023 (₹ Cr)	March 31, 2024 (₹ Cr)
Revenue from operations	651.20	524.63	454.89	1,929.19
Other income	2.40	1.52	1.52	6.52
Total income	653.60	526.15	456.41	1,935.71
Total expenses	522.50	413.31	408.83	1,645.04
Profit before tax	131.10	112.84	47.58	290.67
Net profit	86.01	76.66	31.68	195.79
EPS (Basic & Diluted)	20.70	18.45	7.62	47.12

Consolidated Financial Results for Q1 FY2024-25

Particulars	June 30, 2024 (₹ Cr)	March 31, 2024 (₹ Cr)	June 30, 2023 (₹ Cr)	March 31, 2024 (₹ Cr)
Revenue from operations	651.20	524.63	454.89	1,929.19
Other income	2.40	1.52	1.52	6.57
Total income	653.60	526.15	456.41	1,935.76
Total expenses	522.50	413.31	408.83	1,645.04
Profit before tax	130.96	113.45	47.41	290.75
Net profit	85.87	77.27	31.51	195.87
EPS (Basic & Diluted)	20.67	18.60	7.58	47.14

Conclusion

The Board of Directors expressed confidence in the company's financial health and strategic direction. The approved financial results reflect a solid performance and promising growth prospects for Epigral Limited.